We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
+7.52%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$713M
(+115%)
Cap. Flow
+$1.03B
Cap. Flow
% of AUM
77.19%
Top 10 Holdings %
Top 10 Hldgs %
46.07%
Holding
196
New
82
Increased
39
Reduced
17
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$20M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$18.6M |
| 3 |
Protara Therapeutics
TARA
|
+$12.9M |
| 4 |
BioXcel Therapeutics
BTAI
|
+$12M |
| 5 |
Verastem
VSTM
|
+$11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APTO
Aptose Biosciences, Inc.
APTO
|
+$5.72M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
+$4.63M |
| 3 |
TG Therapeutics
TGTX
|
+$3.51M |
| 4 |
KALA BIO
KALA
|
+$3.39M |
| 5 |
ARQL
Arqule Inc
ARQL
|
+$2.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
iShares Russell 2000 ETF
IWM
$81.4B
| $1.74M | 0.13% |
+15,154
| New | +$2.26M |
|
102
PUT
Minerva Neurosciences
NERV
$190M
| $1.68M | 0.13% |
+34,838
| New | +$2.1M |
|
|
ALBO
103
CALL
DELISTED
Albireo Pharma Inc
ALBO
| $1.65M | 0.12% |
+100,500
| New | +$2.21M |
|
|
IMMU
104
CALL
DELISTED
Immunomedics Inc
IMMU
| $1.56M | 0.12% |
116,100
-332,100
| -74% | -$5.59M |
|
105
PUT
NextCure
NXTC
$17.1M
| $1.51M | 0.11% |
+3,392
| New | +$1.81M |
|
|
106
PUT
Aurinia Pharmaceuticals
AUPH
$1.87B
| $1.45M | 0.11% |
+100,000
| New | +$1.76M |
|
107
Avalo Therapeutics
AVTX
$957M
| $1.4M | 0.11% |
196
+16
| +9% | +$169K |
|
|
APLS
108
DELISTED
Apellis Pharmaceuticals
APLS
| $1.4M | 0.11% |
52,126
+52,073
| +98,251% | +$1.85M |
|
109
CALL
Coherus Oncology
CHRS
$219M
| $1.36M | 0.1% |
84,100
| – | – |
|
|
ALLK
110
CALL
DELISTED
Allakos
ALLK
| $1.33M | 0.1% |
30,000
-128,800
| -81% | -$8.81M |
|
|
ALLK
111
PUT
DELISTED
Allakos
ALLK
| $1.33M | 0.1% |
+30,000
| New | +$2.05M |
|
112
Solid Biosciences
SLDB
$776M
| $1.29M | 0.1% |
+35,937
| New | +$1.78M |
|
|
APTX
113
DELISTED
Aptinyx Inc. Common Stock
APTX
| $1.28M | 0.1% |
+591,000
| New | +$1.93M |
|
|
FLNA
114
Filana Therapeutics
FLNA
$48.3M
| $1.23M | 0.09% |
+300,000
| New | +$1.99M |
|
115
Quince Therapeutics
QNCX
$25.4M
| $1.14M | 0.09% |
+125
| New | +$1.23M |
|
116
Ovid Therapeutics
OVID
$427M
| $1.13M | 0.08% |
377,737
+27,737
| +8% | +$93.5K |
|
117
Protagonist Therapeutics
PTGX
$8.54B
| $1.12M | 0.08% |
158,222
+79,896
| +102% | +$599K |
|
118
CALL
Fate Therapeutics
FATE
$291M
| $1.11M | 0.08% |
+50,100
| New | +$1.27M |
|
|
119
PUT
Fate Therapeutics
FATE
$291M
| $1.11M | 0.08% |
+50,100
| New | +$1.27M |
|
|
120
CALL
Solid Biosciences
SLDB
$776M
| $1.07M | 0.08% |
29,987
+9,614
| +47% | +$476K |
|
121
InflaRx
IFRX
$255M
| $1M | 0.08% |
262,600
-96,528
| -27% | -$358K |
|
122
Mustang Bio
MBIO
$4.37M
| $955K | 0.07% |
475
+44
| +10% | +$113K |
|
|
DBVT
123
DBV Technologies
DBVT
$794M
| $894K | 0.07% |
22,811
+15,357
| +206% | +$1.38M |
|
|
BLU
124
DELISTED
BELLUS Health Inc.
BLU
| $891K | 0.07% |
63,721
| – | – |
|
|
ICAD
125
DELISTED
iCAD Inc
ICAD
| $786K | 0.06% |
+107,103
| New | +$1.04M |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q1 2020 Portfolio in Review
As of Q1 2020, Ikarian Capital held 196 positions worth $1.33B, up 115% from $617M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Ikarian Capital deployed $1.03B of net new capital in Q1 2020, opening 82 new positions and adding to 39 existing holdings. Its largest new stake was Zogenix, Inc.: 549,459 shares worth $13.6M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 16% a quarter earlier.
On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $4.63M trimmed.
- Ikarian Capital's largest Q1 2020 buy was Zogenix, Inc.: 549,459 shares worth $13.6M.
- Ikarian Capital added most to Protara Therapeutics in Q1 2020, an estimated $12.9M increase.
- Ikarian Capital's biggest Q1 2020 reduction was Aurinia Pharmaceuticals, cutting an estimated $4.63M.
- Ikarian Capital fully exited Aptose Biosciences, Inc. in Q1 2020, selling an estimated $5.72M.
- Ikarian Capital's ten largest holdings make up 46% of its $1.33B portfolio in Q1 2020.
- Ikarian Capital opened 82 new positions and closed 45 in Q1 2020.
- Ikarian Capital's portfolio value rose 115% quarter-over-quarter to $1.33B.
Based on Ikarian Capital's 13F filing for Q1 2020, filed 15 May 2020.